RT Journal Article
SR Electronic
T1 Reduced COVID-19 Hospitalizations among New York City Residents Following Age-Based SARS-CoV-2 Vaccine Eligibility: Evidence from a Regression Discontinuity Design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.30.21259491
DO 10.1101/2021.06.30.21259491
A1 Greene, Sharon K.
A1 Levin-Rector, Alison
A1 McGibbon, Emily
A1 Baumgartner, Jennifer
A1 Devinney, Katelynn
A1 Ternier, Alexandra
A1 Sell, Jessica
A1 Kahn, Rebecca
A1 Kishore, Nishant
YR 2021
UL http://medrxiv.org/content/early/2021/07/05/2021.06.30.21259491.abstract
AB Background In clinical trials, several SARS-CoV-2 vaccines were shown to reduce risk of severe COVID-19 illness. Local, population-level, real-world evidence of vaccine effectiveness is accumulating. We assessed vaccine effectiveness for community-dwelling New York City (NYC) residents using a quasi-experimental, regression discontinuity design, leveraging a period (January 12–March 9, 2021) when ≥65-year-olds were vaccine-eligible but younger persons, excluding essential workers, were not.Methods We constructed segmented, negative binomial regression models of age-specific COVID-19 hospitalization rates among 45–84-year-old NYC residents during a post-vaccination program implementation period (February 21–April 17, 2021), with a discontinuity at age 65 years. The relationship between age and hospitalization rates in an unvaccinated population was incorporated using a pre-implementation period (December 20, 2020–February 13, 2021). We calculated the rate ratio (RR) and 95% confidence interval (CI) for the interaction between implementation period (pre or post) and age-based eligibility (45–64 or 65–84 years). Analyses were stratified by race/ethnicity and borough of residence. Similar analyses were conducted for COVID-19 deaths.Results Hospitalization rates among 65–84-year-olds decreased from pre- to post-implementation periods (RR 0.85, 95% CI: 0.74–0.97), controlling for trends among 45–64-year-olds. Accordingly, an estimated 721 (95% CI: 126–1,241) hospitalizations were averted. Residents just above the eligibility threshold (65–66-year-olds) had lower hospitalization rates than those below (63–64-year-olds). Racial/ethnic groups and boroughs with higher vaccine coverage generally experienced greater reductions in RR point estimates. Uncertainty was greater for the decrease in COVID-19 death rates (RR 0.85, 95% CI: 0.66–1.10).Conclusion The vaccination program in NYC reduced COVID-19 hospitalizations among the initially age-eligible ≥65-year-old population by approximately 15%. The real-world evidence of vaccine effectiveness makes it more imperative to improve vaccine access and uptake to reduce inequities in COVID-19 outcomes.Competing Interest StatementRK discloses consulting fees from Partners In Health. Otherwise, the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Funding StatementSKG was supported by the Public Health Emergency Preparedness Cooperative Agreement (grant No. NU90TP922035-02), funded by the US Centers for Disease Control and Prevention (CDC). ALR was supported by ELC CARES (grant No. NU50CK000517-01-09), funded by CDC. RK was supported by the U.S. National Cancer Institute Seronet cooperative agreement U01CA261277. This article's contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC or the Department of Health and Human Services. The funders had no role in study design; data collection, analysis, or interpretation; writing of the article; or in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was deemed public health surveillance that is non-research by the Institutional Review Board of the New York City Department of Health and Mental Hygiene.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analytic dataset for the primary analysis for hospitalizations is provided in Appendix B. Additional publicly available data on COVID-19 hospitalization and death rates and vaccination coverage are linked below. https://www1.nyc.gov/site/doh/covid/covid-19-data.page